Navigation Links
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
Date:10/26/2007

PALO ALTO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 14 non-executive officers due to additional hiring, primarily in connection with its commercialization efforts in the United States.

The inducement stock options cover an aggregate 23,600 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10 year term and vest over four years as follows: 20 percent of these options will vest on the date one year from the optionee's hire date, 20 percent of the options will vest in monthly increments during each of the second and third years, and 40 percent of the options will vest in monthly increments during the fourth year (in all cases subject to the terms and conditions of CV Therapeutics 2004 Employment Commencement Incentive Plan).

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
3. Sonic Foundry reports GAAP loss as Q2 revenues rise
4. Fiserv reports $113.5 million in Q1 profit
5. Third Wave reports net loss of $18.9M for 2006
6. Musicnotes reports 45 percent growth in 2006
7. Sonic Foundry reports net loss, higher revenue
8. Sonic Foundry reports first cash-positive quarter
9. Merge Healthcare reports $10.8M net loss in Q3
10. Third Wave reports $5.2M third quarter loss
11. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015 Pharmaco-Kinesis Corporation (PKC) announced today that ... Shutters on the Beach in Santa Monica, ... the Company,s innovative Metronomic Biofeedback Pump (MBP), a fully ... over time to a target site of the human ... system in real-time.  ...
(Date:5/26/2015)... , May 26, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that all ... 2014 were exercised prior to their expiry on June ... of $11.7 million. "We thank our shareholders ... President and CEO of Asterias. "This exercise of warrants ...
(Date:5/26/2015)... NEW YORK , May 26, 2015 ... NVGN ), announced today that it will present at the ... New York City at the Grand Hyatt ... Kelly , Novogen Chairman and CEO, is scheduled to begin at ... To access the webcast, go to http://wsw.com/webcast/marcum3/nvgn . ...
(Date:5/25/2015)... FL (PRWEB) May 26, 2015 Where ... speaker Jack Uldrich says, "The honest answer is that ... deliver four keynote speeches throughout the month of June, ... keynote topics vary from future-proofing to top tech trends. ... Uldrich's research is where the universe is expanding to. ...
Breaking Biology Technology:Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3Novogen to Present at the 2015 Marcum Microcap Conference 2Novogen to Present at the 2015 Marcum Microcap Conference 3Novogen to Present at the 2015 Marcum Microcap Conference 4Futurist Jack Uldrich Says Embracing Our Ignorance is the Key to Unlearning 2Futurist Jack Uldrich Says Embracing Our Ignorance is the Key to Unlearning 3
... added four, six and eight port right-angle BNC connectors to its ... savings as a replacement for applications where a number of single ... ... Sunnyvale, CA (PRWEB) April 29, 2009 -- Regal Electronics ...
... - 4TB4Free , ... Austin, Texas (PRWEB) April 29, ... for accessing, storing and distributing content, today announced the release of ... can run virtual CAStor nodes in a single, physical server chassis. ...
... MEDX ) is scheduled to host a ... Time on Thursday, April 30, 2009 to review Medarex,s ... of 2009.To access the call live, please dial 1-877-397-0272 ... through the Investor Relations section of Medarex,s website at ...
Cached Biology Technology:Regal Introduces Four, Six and Eight Port Filtered and Un-Filtered Right Angle BNC Connectors 2Caringo Delivers Storage Cluster in a Box with CAStor 3.0 2Medarex to Host Business and Financial Update Conference Call on Thursday, April 30, 2009 2
(Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/8/2015)... SAN JOSE, Calif. , May 8, 2015 ... human interface solutions, today announced that members of the executive ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Westin Waterfront Hotel in Boston, MA ... Date: May 27, 2015 Time: 2:45pm ET Location: The New ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... Our immune system protects us from disease, destroying invading microbes with ... for no apparent reason, ganging up on normal tissues in our ... the immune system attacks the inner ear, home to the tiny, ... or weeks, patients lose the ability to hear in one or ...
... composition of the genetically produced potatoes known as fructan ... differ in the new substances intentionally incorporated with gene ... the Max Planck Institute of Molecular Plant Physiology and ... study published in the Proceedings of the National Academy ...
... a specific mechanism involved in the biology of malignant ... issue of Cancer Cell, significantly advance knowledge about epidermal ... cell surface receptor that stimulates cell growth by transmitting ... often present at abnormally elevated levels in human cancer ...
Cached Biology News:New Lab Research May Help Those Deafened By Immune System Attack 2New Lab Research May Help Those Deafened By Immune System Attack 3New Lab Research May Help Those Deafened By Immune System Attack 4A slight difference and significant similarities 2Physical and functional interaction of key cell growth molecules linked to cancer 2